To measure what is

measurable and

make measurable

what is not so

Galileo Galilei 1564 – 1641

To measure what is

measurable and

make measurable

what is not so

Galileo Galilei 1564 – 1641

To measure what is

measurable and

make measurable

what is not so

Galileo Galilei 1564 – 1641

In Vitro Science

The commitment to Alternatives of millions of scientists around the world and the data generated by the scientific community have created a new science: the In Vitro Science. Since 2001, VitroScreen has played a pivotal role in introducing Alternatives and advancing in Vitro pre-clinical studies in Life Sciences. The company guided by core values of excellence and quality, remains a recognized key player in providing in vitro services from R&D to regulatory acceptance and believes that 3D Micro Physiological Systems are the future of in Vitro Science.

In Vitro Science

History

VitroScreen was founded by Dr. Marisa Meloni, PhD, Pharma D, in 2001, a pioneer with the vision that the In vitro Science was acquiring the power to revolutionize the Life Science industry.

Dr. Meloni envisioned the advantages and sustainability of testing on 3D human tissue models over animals or humans.

This visionary idea has now become integral in almost all industrial contexts such as cosmetics, household products, chemicals, nutritionals, and pharmaceuticals.

In 2021 VitroScreen has been acquired by SenzaGen AB thus becoming member of an international corporate group aiming to be an in vitro testing leader, driving the transition from animal testing to methods better suited to reflect human biology.
With a focus on quality, reliability and customer trust, VitroScreen remains a recognized world leader for in Vitro research and testing based on human models.

MISSION

VISION

MISSION

To provide the best in vitro testing strategy by Robust, Reliable, Predictive, Human relevant non-clinical data.
We are research driven to develop in Vitro Science-based models’ acceptance in toxicology, and preclinical translational research.
We are quality oriented and deploy our efforts to support customers to better meet regulatory requirements.
We flexibly tackle challenges and adopt advanced methodologies applied to customized experimental protocols.

VISION

We strive to be recognized as a highly reliable and customer-focused partner for preclinical testing and R&D needs in Life Sciences.
We focus to develop Alternatives to animal methods investing in state-of-the-art in vitro toxicology.
We want to support customers’ management teams in their efforts towards sustainable innovation in non-clinical projects.

History

VitroScreen was founded by Dr. Marisa Meloni, PhD, Pharma D, in 2001, a pioneer with the vision that the In vitro Science was acquiring the power to revolutionize the Life Science industry.

Dr. Meloni envisioned the advantages and sustainability of testing on 3D human tissue models over animals or humans.

This visionary idea has now become integral in almost all industrial contexts such as cosmetics, household products, chemicals, nutritionals, and pharmaceuticals.

MISSION

VISION

To provide the best in vitro testing strategy by Robust, Reliable, Predictive, Human relevant non-clinical data.
We are research driven to develop in Vitro Science-based models’ acceptance in toxicology, and preclinical translational research.
We are quality oriented and deploy our efforts to support customers to better meet regulatory requirements.
We flexibly tackle challenges and adopt advanced methodologies applied to customized experimental protocols.

We strive to be recognized as a highly reliable and customer-focusedpartner for preclinical testing and R&D needs in Life Sciences.
We focus to develop Alternatives to animal methods investing in state-of-the-art in vitro toxicology.
We want to support customers’ management teams in their efforts towards sustainable innovation in non-clinical projects.

MISSION

VISION

MISSION

To provide the best in vitro testing strategy by Robust, Reliable, Predictive, Human relevant non-clinical data.
We are research driven to develop in Vitro Science-based models’ acceptance in toxicology, and preclinical translational research.
We are quality oriented and deploy our efforts to support customers to better meet regulatory requirements.
We flexibly tackle challenges and adopt advanced methodologies applied to customized experimental protocols.

VISION

We strive to be recognized as a highly reliable and customer-focusedpartner for preclinical testing and R&D needs in Life Sciences.
We focus to develop Alternatives to animal methods investing in state-of-the-art in vitro toxicology.
We want to support customers’ management teams in their efforts towards sustainable innovation in non-clinical projects.

R&D Capabilities

By integrating our team’s expertise and investing in cutting-edge technologies, we are driven by the strongest commitment to innovation and the aspiration to generate robust and scientifically recognized data to support non clinical projects.

VitroScreen has the capability to:

To act as an outsourcing unit for R&D projects in therapeutic areas as diverse as the human body (barriers and organs), developing experimental protocols on advanced 3D systems
To enter in Validation projects of new Alternatives thanks to its experience and its quality-oriented mentality for method validation and resources: GLP and ISO certified, CIR agreement and active member of EU-NETVAL.
To develop customized bioengineered spheroids production within VitroScreen ORA^®platform: advanced tissue-specific miniaturized 3D human organs that mirror the phenotypic characteristics of donor cells and their metabolic pathways.

We are:

R&D Capabilities

VitroScreen has the capability to:

To act as an outsourcing unit for R&D projects in therapeutic areas as diverse as the human body (barriers and organs), developing experimental protocols on advanced 3D systems
To enter in Validation projects of new Alternatives thanks to its experience and its quality-oriented mentality for method validation and resources: GLP and ISO certified, CIR agreement and active member of EU-NETVAL.
To develop customized bioengineered spheroids production within VitroScreen ORA^®platform: advanced tissue-specific miniaturized 3D human organs that mirror the phenotypic characteristics of donor cells and their metabolic pathways.

We are: